Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To CompetitorsMarketWatch Automated·1 day ago, 04:22 PMCRBP+1.63%
Corbus Q2 FY26 net loss widens to $35.04 million; loss per share increases to $1.81PUBT·Aug 6 at 07:04 AMCRBP+1.63%
Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·Aug 4 at 04:20 PMCRBP+1.63%
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statementPUBT·Aug 4 at 03:31 PMCRBP+1.63%
Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visitPUBT·Aug 4 at 07:33 AMCRBP+1.63%
Corbus Pharmaceuticals Holdings Inc. Stock Rises Thursday, Still Underperforms MarketMarketWatch Automated·Jul 30 at 04:21 PMCRBP+1.63%
CSPC says FDA clears CRB-701 pivotal trial in second-line oropharyngeal cancerPUBT·Jul 29 at 07:34 AMCRBP+1.63%01093-0.29%
Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The DayMarketWatch Automated·Jul 24 at 04:21 PMCRBP+1.63%
